BioAge Labs (NASDAQ:BIOA) Trading Down 5.9% – What’s Next?

BioAge Labs, Inc. (NASDAQ:BIOA)’s share price dropped 5.9% during trading on Wednesday . The company traded as low as $20.00 and last traded at $19.9650. Approximately 39,100 shares traded hands during trading, a decline of 95% from the average daily volume of 746,315 shares. The stock had previously closed at $21.22.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Citigroup raised their price target on shares of BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a report on Tuesday, March 10th. Oppenheimer began coverage on BioAge Labs in a report on Wednesday, February 25th. They set an “outperform” rating and a $60.00 price target for the company. Wall Street Zen raised BioAge Labs from a “sell” rating to a “hold” rating in a research report on Tuesday, February 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Tuesday, January 27th. Finally, Piper Sandler began coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They set an “overweight” rating for the company. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $45.00.

BioAge Labs Stock Down 7.7%

The firm has a market cap of $702.30 million, a price-to-earnings ratio of -12.85 and a beta of 1.22. The company’s 50-day moving average price is $19.94 and its 200-day moving average price is $12.34.

Insiders Place Their Bets

In other news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $18.75, for a total transaction of $139,368.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kristen Fortney sold 233,107 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $18.12, for a total transaction of $4,223,898.84. Following the completion of the sale, the chief executive officer directly owned 976,949 shares in the company, valued at approximately $17,702,315.88. This trade represents a 19.26% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 267,540 shares of company stock worth $4,895,168 in the last ninety days. 20.82% of the stock is owned by corporate insiders.

Institutional Trading of BioAge Labs

Several institutional investors have recently modified their holdings of BIOA. Invesco Ltd. purchased a new position in shares of BioAge Labs in the 4th quarter valued at $3,025,000. XTX Topco Ltd acquired a new position in BioAge Labs in the fourth quarter valued at $486,000. Sphera Funds Management LTD. purchased a new position in shares of BioAge Labs during the fourth quarter worth about $3,215,000. Quadrature Capital Ltd increased its position in shares of BioAge Labs by 56.2% during the fourth quarter. Quadrature Capital Ltd now owns 16,769 shares of the company’s stock worth $222,000 after purchasing an additional 6,035 shares in the last quarter. Finally, Janus Henderson Group PLC purchased a new stake in shares of BioAge Labs in the 4th quarter valued at about $5,406,000.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.